Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
By Nate Raymond BOSTON, May 18 (Reuters) - A U.S. jury on Monday found Japan-based Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme.